Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL Current Therapeutic Research-clinical and Experimental Pub Date : 2023-01-01 DOI:10.1016/j.curtheres.2023.100715

Pegah Shakib PhD , Masoomeh Zivdari MSc , Amal Khudair Khalaf PhD , Abdolrazagh Marzban PhD , Mazdak Ganjalikhani-Hakemi PhD , Jahanbakhsh Parvaneh MD , Hossein Mahmoudvand PhD , Kourosh Cheraghipour PhD

{"title":"Nanoparticles as Potent Agents for Treatment of Schistosoma Infections: A Systematic Review","authors":"Pegah Shakib PhD , Masoomeh Zivdari MSc , Amal Khudair Khalaf PhD , Abdolrazagh Marzban PhD , Mazdak Ganjalikhani-Hakemi PhD , Jahanbakhsh Parvaneh MD , Hossein Mahmoudvand PhD , Kourosh Cheraghipour PhD","doi":"10.1016/j.curtheres.2023.100715","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus <em>Schistosoma</em>. The current drugs for treating schistosomiasis are associated with some side effects.</p></div><div><h3>Objective</h3><p>The aim of this systematic study was an overview of the treatment of diseases caused by <em>Schistosoma</em> based on nanoparticles.</p></div><div><h3>Methods</h3><p>In the present systematic research with keywords “<em>Schistosoma</em>”, “parasitism”, “anti-<em>Schistosoma</em> activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “<em>in vitro</em>”, and “<em>in vivo</em>” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.</p></div><div><h3>Results</h3><p>In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against <em>Schistosoma</em> were gold nanoparticles (22%).</p></div><div><h3>Conclusions</h3><p>The results indicate the high potential of various nanoparticles, including metal nanoparticles, against <em>Schistosoma</em>. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. <em>Ther Res Clin Exp</em>. 2023; XX:XXX–XXX).</p></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"99 ","pages":"Article 100715"},"PeriodicalIF":1.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X23000243","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Schistosomiasis is an acute and chronic parasitic disease caused by blood flukes of the genus Schistosoma. The current drugs for treating schistosomiasis are associated with some side effects.

Objective

The aim of this systematic study was an overview of the treatment of diseases caused by Schistosoma based on nanoparticles.

Methods

In the present systematic research with keywords “Schistosoma”, “parasitism”, “anti-Schistosoma activity”, “nanoparticles”, “metal nanoparticles”, “silver nanoparticles”, “gold nanoparticles”, “polymer nanoparticles”, “PLGA nanoparticles”, “nanoemulsions”, “in vitro”, and “in vivo” from five English-language databases, including ScienceDirect, europePMC, PubMed, Scopus, Ovid, and Cochrane were searched from 2000 to 2022 by 2 researchers.

Results

In the initial search, 250 studies were selected. Based on the inclusion and exclusion criteria, 27 articles were finally selected after removing duplicate, unrelated, and articles containing full text. In present article, the most nanoparticles used against Schistosoma were gold nanoparticles (22%).

Conclusions

The results indicate the high potential of various nanoparticles, including metal nanoparticles, against Schistosoma. Also, the remarkable anti-schistosomal activity of nanoparticles suggests their use in different fields to eliminate this pathogenic microorganism so that it can be used as an effective candidate in the preparation of anti-schistosomal compounds because these compounds have fewer side effects than chemical drugs. Ther Res Clin Exp. 2023; XX:XXX–XXX).

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

纳米粒子作为治疗血吸虫感染的有效药物：系统综述

背景血吸虫病是由血吸虫属吸虫引起的一种急慢性寄生虫病。目前治疗血吸虫病的药物有一些副作用。目的本系统研究的目的是综述基于纳米颗粒的血吸虫病治疗方法。方法以“血吸虫”、“寄生”、“抗血吸虫活性”、“纳米粒子”、“金属纳米粒子”、银纳米粒子、“金纳米粒子”、聚合物纳米粒子、PLGA纳米粒子、纳米乳液、体外和体内为关键词，从ScienceDirect等五个英文数据库中进行系统研究，2名研究人员从2000年到2022年搜索了europePCM、PubMed、Scopus、Ovid和Cochrane。结果在最初的搜索中，选择了250项研究。根据纳入和排除标准，在删除重复、无关和包含全文的文章后，最终选择了27篇文章。在本文中，抗血吸虫病的纳米颗粒以金纳米颗粒最多（22%）。结论包括金属纳米颗粒在内的各种纳米颗粒对血吸虫病具有很高的抗药性。此外，纳米颗粒显著的抗血吸虫活性表明，它们在不同领域都可以用来消除这种致病微生物，因此可以作为制备抗血吸虫化合物的有效候选者，因为这些化合物的副作用比化学药物少。Ther Res临床实验2023；XX： XXX–XXX）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Therapeutic Research-clinical and Experimental 医学-药学

CiteScore

3.50

自引率

0.00%

发文量

审稿时长

3 months

期刊介绍： We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics. CTR encourages and supports the submission of manuscripts describing: • Interventions designed to understand or improve human health, disease treatment or disease prevention; • Studies that focus on problems that are uncommon in resource-rich countries; • Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing); • Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English; • Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.